10-Q: Plexus Corp. Reports Q3 2024 Results: Sales Dip Amid Market Corrections, Profitability Improves

Plexus Corp. experienced a decrease in net sales during the third quarter of 2024 due to market-driven inventory corrections and weaker demand, but saw improved profitability due to a positive shift in customer mix and reduced restructuring charges.

Summary

• Plexus Corp.'s net sales for the third quarter of 2024 decreased by 6.0% to $960.8 million compared to $1,021.6 million in the same period last year.
• The company's gross profit increased slightly to $94.4 million, with a gross margin of 9.8%, up from 9.2% year-over-year.
• Operating income for the quarter rose significantly to $39.2 million, compared to $28.2 million in the prior year, with an operating margin of 4.1%.
• Net income for the quarter increased to $25.1 million, or $0.91 per diluted share, compared to $15.8 million, or $0.56 per diluted share, in the third quarter of 2023.
• For the first nine months of 2024, net sales decreased by 8.7% to $2,910.3 million, while net income decreased to $70.6 million, or $2.53 per diluted share.
• The company experienced market-driven inventory corrections at customers and weaker demand in the Healthcare/Life Sciences and Industrial sectors.
• Plexus anticipates improvements in market conditions and demand in certain sectors into fiscal year 2025.
• The company's cash and cash equivalents were $270 million, with $349 million in debt, finance lease, and other financing obligations.

Sentiment

Score: 5

Explanation: The document presents mixed results with a decrease in sales but an increase in profitability. The company faces challenges but also has some positive developments. The sentiment is neutral to slightly negative due to the overall decrease in sales and net income for the nine-month period.

Positives

• Gross margin improved due to a positive shift in customer mix.
• Operating income increased significantly due to higher gross profit and lower restructuring charges.
• The EMEA region showed strong growth in net sales.
• The Aerospace/Defense sector experienced significant growth in net sales.
• Free cash flow improved significantly due to lower working capital investments in inventory and favorable accounts payable activity.
• The company has $350 million available under its revolving credit facility, with the ability to expand to $750 million.

Negatives

• Net sales decreased due to market-driven inventory corrections and weaker demand in the Healthcare/Life Sciences and Industrial sectors.
• The AMER and APAC regions experienced decreases in net sales.
• Net income for the first nine months of 2024 decreased compared to the same period in 2023.
• The company experienced a decrease in net sales in the Healthcare/Life Sciences and Industrial sectors.
• The company anticipates a material and unfavorable impact on its tax rate beginning in fiscal 2025 due to a global minimum tax.

Risks

• Continued market softness could impact future operating results.
• The company faces risks related to customer delays, changes, cancellations, and forecast inaccuracies.
• There are risks associated with excess and obsolete inventory.
• The company is exposed to fluctuations in currency values and interest rates.
• The company faces increasing regulatory and compliance requirements.
• The company is exposed to potential barriers to the repatriation of funds held outside the United States.
• The company is exposed to potential effects of jurisdictional results on taxes, tax rates, and the ability to use deferred tax assets and net operating losses.

Future Outlook

Plexus anticipates improvements in market conditions and demand in certain sectors into fiscal year 2025, but also expects a material and unfavorable impact on its tax rate beginning in fiscal 2025 due to a global minimum tax.

Management Comments

• Management measures operational performance and allocates resources on a geographic segment basis.
• Our global business development strategy is based on our targeted market sectors.
• We believe our balance sheet is positioned to support the potential future challenges presented by the macro-economic pressures we are facing.
• Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents, potential borrowings under the Credit Facility and our leasing capabilities should be sufficient to meet our working capital and fixed capital requirements, as well as execution upon our share repurchase authorizations as management deems appropriate, for the next twelve months.

Industry Context

The report reflects challenges in the Electronic Manufacturing Services (EMS) industry, with market-driven inventory corrections and weaker demand impacting sales. However, the company's focus on high-complexity products and diverse sectors like Healthcare/Life Sciences, Industrial, and Aerospace/Defense provides some resilience.

Comparison to Industry Standards

• Plexus's gross margin of 9.8% in Q3 2024 is relatively low compared to some of its peers in the EMS industry, which can range from 10% to 15% or higher, depending on the specific business model and market focus.
• Companies like Jabil and Flex, which are larger players in the EMS sector, often report higher gross margins due to their scale and diversified service offerings.
• Plexus's operating margin of 4.1% in Q3 2024 is also lower than some of its competitors, which can achieve operating margins in the range of 5% to 8% or higher.
• The company's focus on high-complexity products and demanding regulatory environments may lead to higher costs, impacting margins compared to companies with a broader range of products and services.
• Plexus's ROIC of 10.4% for the nine months ended June 29, 2024, is below its target of 15%, indicating a need for improved capital efficiency.
• The company's economic return of 2.2% for the same period suggests that it is generating value for shareholders, but there is room for improvement to meet its internal goals.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net sales and net income for the nine-month period.
• Employees may be affected by restructuring activities and workforce reductions.
• Customers may experience changes in lead times and pricing due to market conditions.
• Suppliers may be impacted by changes in demand and procurement patterns.
• Creditors may be concerned about the company's debt levels and ability to meet its obligations.

Next Steps

• The company will continue to monitor market conditions and demand in various sectors.
• Plexus will focus on improving capital efficiency to achieve its ROIC target.
• The company will continue to execute its share repurchase program.
• Plexus will monitor the implementation of global minimum tax laws and their impact on the company's tax rate.

Key Dates

Keywords

Electronic Manufacturing Services, EMS, Manufacturing, Supply Chain, Healthcare/Life Sciences, Industrial, Aerospace/Defense, Net Sales, Gross Profit, Operating Income, Net Income, Share Repurchase, Inventory, Restructuring, Economic Return, ROIC